Seattle, WA -- (SBWIRE) -- 09/24/2019 -- Dengue is a mosquito-borne tropical disease that is caused by dengue virus. Dengue causes excruciating bone and joint pain, which is why it is also referred as break bone fever. It was first discovered in Philippines and Thailand in 1950s, which was epidemic. Since then, it has spread in Latin American as well as Asia Countries, which has been the leading cause of hospitalization and increased rates in mortality among children and adults. There are four types of dengue viruses namely DEN-1, DEN-2, DEN-3 and DEN-4 though there are no therapeutics available for treatment of these viruses. Therefore, the sole focus in dengue treatment is to control the vectors being home.
Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/23
Prevalent Scenario in the Global Dengue Vaccines Market
Member states in three of the WHO regions regularly report the annual number of dengue cases. These statistic suggest that the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO) mentions that there are around 390 million dengue cases worldwide each year, with number of cases reported increasing each year. In 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue that led to 1,181 deaths. Dengue is a pertinent health issue affecting people across South America, Europe, and Asia. A large number of dengue outbreaks were reported worldwide in 2015, with over 169,000 cases in the Philippines and over 111,000 suspected cases of dengue in Malaysia. This was a staggering 59.5% and 16% increase respectively in the number of cases compared to that in 2014. The global dengue vaccines market therefore, offers lucrative growth opportunities for vaccine manufacturers.
Global Dengue Vaccines Market – Dynamics
Increasing demand for dengue vaccines around the world due to increased dengue outbreaks is expected to drive the global dengue vaccines market growth during the forecast period 2018-2026. Key companies in the market are focused on various business strategies such as partnerships and collaborations, in order to jointly develop novel vaccines for dengue. For instance, in November 2018, GlaxoSmithKline Vaccines (GSK) in collaboration with Walter Reed Army Institute of Research (WRAIR) developed a live-attenuated tetravalent dengue virus vaccine candidate comprised of four live virus strains representing each of the four DENV types. Currently, it is being evaluated in Phase I human testing. Furthermore, in December 2018, Merck & Co., Inc. and Instituto Butantan entered into collaboration agreement to develop vaccines to protect against dengue infections Moreover, increasing product approvals by regulatory authorities is expected to drive the market growth. For instance, in May 2019, the U.S. Food and Drugs Administration (FDA) approved the first vaccine 'Dengvaxia', against dengue fever caused by serotypes 1-4 of the virus in individuals aged between 9 and 16 years living in endemic areas of the U.S.
Dengvaxia – the only approved product in the global dengue vaccines market
Sanofi Pasteur's Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the world's first licensed vaccine for prevention of dengue. It is a tetravalent dengue vaccine that prevents the disease from all four dengue viruses in people aged 9 to 45 years. Sanofi launched the world's first public dengue vaccination program in the Philippines (2016), followed by Brazil. Dengvaxia is approved in 10 endemic countries worldwide, namely, Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. The global dengue vaccines market is thus, expected to expand with growing market approvals.
India is however taking a precautionary approach in approving this vaccine due to lack of studies among the population in the country. A scientist in India has developed a dengue vaccine that was successfully tested in monkeys. If successful in human trials, this could be a breakthrough invention for prevention of dengue among the populace in the country. Moreover, various philanthropists and global organizations are investing in developing vaccines for malaria and dengue.
For More Details, Click @ https://www.coherentmarketinsights.com/ongoing-insight/dengue-vaccines-market-23
Dengue Vaccines Market Outlook – Research Pipeline
There are approximately five vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Also, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. In September 2016, Takeda announced the beginning of the phase 3 clinical trials of its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains.
Key developments
- Increasing approval of vaccines by regulatory authorities is expected drive the global dengue vaccines market growth in the near future. For instance, in May 2019, the U.S. Food and Drugs Administration (FDA) approved the first vaccine 'Dengvaxia', against dengue fever caused by serotypes 1-4 of the virus in individuals aged between 9 and 16 years living in endemic areas of the U.S.
- Key players in the market are developing novel vaccines for dengue to gain competitive edge in the market. For instance, in November 2018, GlaxoSmithKline Vaccines (GSK) in collaboration with Walter Reed Army Institute of Research (WRAIR) developed a live-attenuated tetravalent dengue virus vaccine candidate comprised of four live virus strains representing each of the four DENV types. Currently, it is being evaluated in Phase I human testing.
- Key players in the market are involved in various business strategies such as partnership and collaboration to develop new vaccines against dengue. For instance, in December 2018, Merck & Co., Inc. and Instituto Butantan entered into collaboration agreement to develop vaccines to protect against dengue infections.
Click To Buy Dengue Vaccines Market Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/23
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.